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Introduction: Discussion about the intensity of warfarin in patients with antiphospholipid
syndrome (APS) remains present in our days.
Objectives: To evaluate which intensity of anticoagulation with warfarin is associated with
a  greater reduction of thromboembolic events in the treatment of patients with APS, as well
as  assess the risk of bleeding in the different treatment modalities.
Methodology: A systematic review of the literature was carried out with search from elec-
tronic databases: PubMed, LILACS and SciELO, with the use of the key-words: treatment,
warfarin,  antiphospholipid syndrome, antiphospholipid antibody syndrome and their respective
translations into Portuguese, in different combinations. In addition, a meta-analysis with
the  aid of Review Manager 5.2 software by Cochrane was performed.
Results: Only two articles met the inclusion criteria for this study. Regarding the main
outcome assessed in this study, the two studies showed similar values, indicating higher
frequency of thrombotic events in high-intensity groups. The comparative analysis of the
randomized clinical trial evaluated showed an increased thrombotic risk for those patients
who  received intervention with high-intensity warfarin. Another ﬁnding of the meta-
analysis was the higher incidence of minor bleeding, also in the experimental group, that
received warfarin keeping International Normalized Ratio (INR) > 3.
Conclusion: In individuals with APS and prevalence of venous events, the use of moderate
intensity (MI) anticoagulation (INR: 2-3) is the most suitable. However, this evidence cannot
yet  be extended to patients with arterial events, due to the limited representation of thissample of subjects in the two clinical trials included in this meta-analysis.
©  2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: jotafc@gmail.com (J.F.d. Carvalho).
ttp://dx.doi.org/10.1016/j.rbre.2014.08.015
255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Intensidade  da  anticoagulac¸ão  no  tratamento  da  trombose  na  síndrome
antifosfolípide:  meta-análise
Palavras-chave:
Síndrome antifosfolípide
Trombose
Hemorragia
Varfarina
r  e  s  u  m  o
Introduc¸ão: a discussão sobre a intensidade de varfarina em pacientes com síndrome antifos-
folípide (SAF) permanece presente nos dias atuais.
Objetivos: avaliar qual intensidade de anticoagulac¸ão com varfarina está associada com
maior  reduc¸ão de eventos tromboembólicos no tratamento de pacientes com SAF, assim
como  avaliar o risco de hemorragia nas diferentes modalidades de tratamento.
Metodologia: foi realizada uma revisão sistemática da literatura a partir de busca nas bases
de  dados eletrônicos: PubMed, LILACS e SciELO, sendo utilizadas as palavras-chave: treat-
ment,  warfarin, antiphospholipid syndrome, antiphospholipid antibody syndrome e suas respectivas
traduc¸ões para o português, em diferentes combinac¸ões. Também foi realizada uma  meta-
análise com auxílio do programa Review Manager 5.2 da Cochrane.
Resultados: apenas dois artigos preencheram os critérios para inclusão neste estudo. Em
relac¸ão  ao principal desfecho avaliado neste trabalho, os dois estudos apresentaram val-
ores similares, demonstrando maior frequência de eventos trombóticos nos grupos de alta
intensidade. A análise comparativa dos ensaio clínicos randomizados avaliados demon-
strou um risco trombótico aumentado para aqueles pacientes que receberam intervenc¸ão
com  varfarina em alta intensidade. Outro achado da meta-análise foi a maior ocorrência de
hemorragia menor também no grupo experimental, que recebeu varfarina mantendo Razão
Normalizada Internacional (RNI) > 3.
Conclusão: nos indivíduos com SAF e predominância de eventos venosos, o uso de
anticoagulac¸ão  em moderada intensidade (MI) (RNI: 2-3) está mais indicado. Por outro lado,
essa  evidência ainda não pode ser estendida aos pacientes com eventos arteriais, pela lim-
itada representac¸ão dessa amostra de sujeitos nos dois estudos clínicos incluídos nesta
meta-análise.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Antiphospholipid syndrome (APS) is an acquired autoimmune
condition consisting of thromboembolic and/or obstetric
events in the presence of circulating antiphospholipid anti-
bodies (aPLs) in plasma (anticardiolipin antibodies [aCL], lupus
anticoagulant [LAC] and anti-2 glycoprotein I [anti-2GPI]).1,2
Thrombosis, both venous and arterial, is the most common
clinical manifestation and the one that causes more  morbidity
in APS.3 Venous thromboembolism is present in about 55% of
these patients4, mainly characterized by deep vein thrombosis
(DVT) and pulmonary embolism (PE). The most common arte-
rial thrombotic manifestations are cerebrovascular accident
(CVA) and transient ischemic attack (TIA), affecting approxi-
mately 50% of patients with APS.1,4,5
The treatment of APS that is currently applied includes:
(1) antiplatelet agents (aspirin or clopidogrel); (2) low molecu-
lar weight heparin and (3) warfarin,6 thus not differing from
the treatment offered to the general population presenting
thrombotic event.7
In the management of patients on anticoagulant med-
ication, a strict monitoring is essential in order to reach
therapeutic doses and do not cause adverse effects.8 An INR
between 2 and 3 presented by patients on warfarin reﬂects
anticoagulant treatment of moderate intensity (MI), which is
the most used and recommended in the scientiﬁc literature.9
However, an INR> 3, which represents high-intensitytreatment (HI), is indicated by some previous work as
the best option in some cases, in secondary prophylaxis of
thrombosis in APS.7,10–12 Most of these studies is partially
based on retrospective cohort suggesting increased risk of
recurrent thrombosis in patients on MI warfarin therapy as
compared to treatment of HI.13–19 Therefore, the discussion
about the intensity of warfarin for secondary prophylaxis of
thrombosis in patients with APS remains present nowadays.
Another controversial issue, when articles comparing the
two intensities of warfarin (MI versus HI) in the treatment of
patients with presence of aPLs are analyzed, is the occurrence
of bleeding, one of the most dreaded complications of antico-
agulant therapy that has a frequency of 2%-3% per year (major
bleeding), similar to that of patients without APS also under-
going anticoagulation.20 There is a strong correlation between
the intensity of anticoagulation and the incidence of bleeding
events. In fact, Levine et al.21 say that we already have good
evidence that the treatment with vitamin K antagonists (eg.
Warfarin) with INR between 2-3 is associated with lower rates
of bleeding when compared to treatment of major intensity
(INR > 3). Thus, when evaluating the reduction of thrombotic
events with anticoagulant treatment, the associated risk of
bleeding complications should also be considered.21
Thus, the mode of use of warfarin in clinical practice
is still in debate today, particularly among rheumatologists,
hematologists and clinicians who deal with the prevention
of recurrent thrombosis in patients with APS. Standardiza-
tion in this direction would help in the proper management
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Research project
Study Identification
Researcher 1 Researcher 2
Consensus on selection
of articles (2615)
2,574 articles excluded
(other study designs)
41 articles included
(randomized clinical trials)
39 did not meet the
other inclusion
criteria
2 met inclusion
criteria
Excluded Selected for
systematic review
and meta-analysis
Figure 1 – Flowchart of methodology adopted in ther e v b r a s r e u m a t o l
f these individuals, reducing rates of morbidity and mortal-
ty, mainly represented by the frequency of thrombotic events
nd complications, such as bleeding.
Therefore, the aim of this study was to evaluate which
ntensity of anticoagulation with warfarin (conventional/MI
s. HI) is associated with greater reduction of thromboembolic
vents in the treatment of patients with APS. As a secondary
ndpoint, the risk of bleeding according to the different inten-
ities of anticoagulation will be assessed.
ethodology
tudy  design
ystematic review of literature and meta-analysis.
earch  strategy
 search was performed in electronic databases: PubMed,
ILACS and SciELO, covering the period from 1983 (when
PS was described) to April 2013. The following key-words
ere used: treatment, warfarin (Wisconsin Alumni Research
oundation), antiphospholipid syndrome, antiphospholipid
ntibody syndrome and their respective translations into
ortuguese, in different combinations. The references of all
elected articles were also evaluated in search for work that
as not identiﬁed in the initial search. There were no language
estrictions.
nclusion  and  exclusion  criteria
cientiﬁc papers that have the design of a randomized clinical
rial (RCT) were selected to assess the use of warfarin for sec-
ndary prophylaxis of thrombosis in APS in patients older than
8 years. Any other study type was excluded from this review,
s well as subgroup analyzes of randomized clinical trials.
The studies had to: (1) present interventions with warfarin
arried out in accordance with the conventional treatment
INR: 2-3) and with high-intensity treatment (INR: 3.1 to 4.5);
2) have each therapy compared with placebo/control group
r compared to each other (conventional/MI vs. HI); (3) assess
s primary endpoint the occurrence of recurrent thrombotic
vents and bleeding, and (4) classify bleeding as total, major
nd minor.
Patients selected for the studies participating in this review
hould also meet Sapporo22 and/or Sydney criteria23 for the
iagnosis of APS. The former include laboratory determina-
ions of anticardiolipin of immunoglobulin G (IgG) and/or
 (IgM) subtypes, and LAC in patients with arterial/venous
hrombosis or episode of fetal loss. Sydney criteria require at
east one clinical and one laboratory criterion (involving the
resence of anti-2-GPI IgG and/or IgM subtypes).
ata  selectionhe two authors of this article conducted a search individu-
lly and decided on consensus (according to predetermined
ethodology) for the selection of items participating in this
eview.selection of studies included in this review.
Fig. 1 summarizes the methodology followed in this sys-
tematic review and meta-analysis for the selection of studies.
Studies  qualitative  evaluation
The scientiﬁc papers selected were also subjected to qual-
itative evaluation through the application of Jadad scale.24
Studies that had grade 3 or greater on the Jadad scale were
characterized as of good quality. In order to strengthen the
assessment of the methodological quality of studies to be
included in the review, the scale of Downs & Black was also
applied.25 This method consists of a questionnaire containing
27 items. It evaluates: information, external validity, inter-
nal validity - bias, confounding (selection bias) and study
power. For each question, the article may receive a score
of 0 or 1, with the exception of question 5, which can
generate 2 points. Each item can get a maximum of 28
points.
Statistics  analysisFor the analysis of dichotomous endpoints some statistical
methods are used by the meta-analysis through the Review
Manager 5.2 software, by Cochrane.26 The statistical method
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Table 1 – Characteristics of studies evaluating the use of warfarin for secondary prophylaxis of thrombosis in patients
with APS, from INR of moderate and high intensity.
Author; year Type of study Jadad
Scale
Downs &
Black Scale
N Length of
follow-up (years)
Age  (years) Female gender
Crowther et al.,
200330
Randomized,
double blind,
multicenter
clinical trial
5  21 MI: 58
HI: 56
MI:  2,7
HI: 2,6
MI: 41 (21-81)
HI: 43 (20-80)
MI: 41 (70.7%)
HI: 27 (48.2%)
Finazzi et al.,
200531
Randomized,
multicenter
clinical trial
3  21 MI: 55
HI: 54
MI:  3,3
HI: 3,5
MI: 41 ± 12.3
HI: 41.1 ± 12.1
MI: 35 (63.6%)
HI: 33 (61.1%)
; INR,HI, high intensity; MI, moderate intensity; N, number of participants
used was the classical Mantel-Haenszel.27–29 The ﬁxed-effect
model was chosen as analysis model, and the risk ratio as a
measure of effect. A p-value of less than or equal to 0.05 was
considered as statistically signiﬁcant, with the adoption of a
conﬁdence interval (CI) of 95%.
Results
Two articles met  the inclusion criteria for this study. Both are
randomized trials that addressed the intensity of warfarin
used in the treatment of patients with APS and were published
in sequence in the years 2003 and 2005.30,31
Both studies, by Crowther et al.30 and Finazzi et al.,31
included in this analysis, scored 21 on Downs & Black scale,25
corresponding to more  than 70% of the questions, therefore
suggesting studies of good methodological quality. Further-
more, those selected clinical trials had grade 3 or greater on
Jadad scale,24 also classifying the included work as of good
quality.
The main characteristics of the studies included in this
review, including its methodological evaluations, number
of participants, and demographic data are summarized on
Table 1.
Although the beginning of data collection was almost
simultaneous, the follow-up time was slightly higher in the
European study (Finazzi),31 being held for 3.5 years in the
group of HI and 3.3 years for the group with conventional treat-
ment. The Canadian study (Crowther)30 presented 2.7 and 2.6
years of follow-up, respectively, for groups of MI and HI.
The studies showed a similar number of participants
(Crowther et al.30 = 114; Finazzi et al.31 = 109), that were prop-
erly randomized into two groups: those who received HI
warfarin therapy (with an INR of 3-4.5 for Finazzi et al.31 and
of 3.1-4 for Crowther et al.30) and those who would be in
the MI  group with an INR between 2-3. However, the clinical
trial by Finazzi et al.31 was just blind on outcomes evaluation,
as opposed to Crowther et al.,30 which was double-blinded,
decreasing potential biases considerably.
Both studies also showed as limitation the premature
discontinuation of clinical care when the HI group had sig-
niﬁcantly higher rates of thrombotic events compared to the
control group.
The RCT by Crowther et al.30 recruited their patients from
tertiary care clinics of rheumatology and thromboembolism
and had as one of its inclusion criteria patients with positivity international normalized ratio; APS, antiphospholipid syndrome.
for aPLs (LAC and/or aCL) and conﬁrmed history of arterial
and/or venous thrombosis. On the other hand, the RCT by
Finazzi et al. 31 selected their patients from 26 centers in four
European countries and Argentina. In line with the Canadian
study, their inclusion criteria were similar.
Regarding the characteristics of the population evaluated
in the studies included in this review, the average age was sim-
ilar (Crowther et al.30 = 42 years; Finazzi et al.31 = 40,5 years).
However, despite the similar percentage of women in the
Canadian study30 there is a major disparity among random-
ized groups (MI: 71% of women; HI: 48% of women). None of
the studies provided information about the patients’ color,
but probably the majority is certainly white, due to the places
where the scientiﬁc work was carried out.
When evaluating the study by Crowther et al.,30 something
that called the attention was a large percentage of patients
who left the study.31 There was only 8.2% of this type of
loss to follow-up. However, there were no deaths in the ﬁrst
study, except for the European RCT,31 which reported ﬁve
deaths.
Analysis of prothrombin time, from INR, to control treat-
ment, was observed in both studies, which showed similar
mean values (Crowther et al.30 = 3.3 HI and 2.3 MI;  Finazzi
et al.31 = 3.2 HI and 2.5 MI).
Regarding the main endpoint assessed in this study,
the two studies showed similar values, indicating higher
frequency of thrombotic events in HI groups (Crowther
et al.30 = 14.2% AI vs.  3.6% MI; Finazzi et al.31 = 11.1% HI vs.  5.5%
MI).
As a secondary endpoint observed in anticoagulant ther-
apy, the frequency of bleeding was evaluated. Finazzi et al.31
deﬁned major bleeding as one that required transfusion or
surgery, fatal, retroperitoneal or intracranial hemorrhage. All
other types of bleeding were classiﬁed as minor hemorrhage.
Hemorrhage, in total, appeared in 25% of HI vs. 19% of MI  in the
Canadian study,30 and in 27.8% of HI vs.  14.6% of MI  in the Euro-
pean study.31 The major hemorrhagic event was also assessed
separately, being present in 5.3% of HI vs. 6.8% of MI  (Crowther
et al.30) and in 3.7% of HI vs.  5.5% of MI (Finazzi et al.31). Finally,
the presence of minor hemorrhage in the European study31
was higher in the HI group - 27.8% of HI vs. 10.9% of MI  - and
was not separately evaluated in the Canadian work.30Table 2 summarizes the main endpoints evaluated in the
studies involved in this systematic review.
The comparative analysis of RCTs evaluated, performed
in this study, demonstrated an increased thrombotic risk for
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Table 2 – Main outcomes evaluated in the studies selected for this review.
Author; year Thrombotic
Event
HR
(95%  IC)
Minor
Hemorrhage
HR
(95%  CI)
Major
Hemorrhage
HR
(95%  CI)
Total of
bleeding
HR
(95% CI)
death HR
(95% CI)
Crowther et al.,
200330
MI: 2/58
(3.4%)
HI: 8/56
(14,2%)
3.1
(0.6-15)
MI: NA
HI: NA
NA MI: 4/58
(6.8%)
HI: 3/56
(5.3%)
1
(0.2-4.8)
MI:  11/58
(18.9%)
HI: 14/56
(25.0%)
1,9
(0.8 – 4.2)
MI: 0/58
HI: 0/56
NA
Finazzi et al.,
200531
MI: 3/55
(5.4%)
HI: 6/54
(11.1%)
1.97
(0.49-7.89)
MI: 6/55
(10.9%)
HI: 15/54
(27.7%)
2.92
(1.13-7.52)
MI:  3/55
(5.4%)
HI: 2/54
(3.7%)
0.66
(0.11-3.96)
MI:  8/55
(14.5%)
HI: 15/54
(27.7%)
2,18 (0,92
– 5,15)
MI: 2/55
(3.6%)
HI: 3/54
(5.5%)
1.41 (0.23
– 8.47)
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aHI, high intensity; CI, conﬁdence interval; HR, hazards ratio;  MI, mode
hose patients who received intervention with HI warfarin
ompared to the group randomized to conventional antico-
gulant treatment. Another ﬁnding of the meta-analysis was
he higher incidence of minor hemorrhage also in the experi-
ental group, that received warfarin keeping an INR > 3.
The graphs of this meta-analysis results (Forest Plot)
ddressing the analysis of outcomes - thrombotic events, total
leeding, major bleeding, minor bleeding and death - are illus-
rated in Figs. 2–6, respectively.
iscussion
his study conducted a meta-analysis of outcomes of throm-
osis and hemorrhage of the articles in the scientiﬁc literature
hat evaluated different intensities of anticoagulation in the
reatment of thrombosis in patients with APS.
Analyzing the available scientiﬁc literature on the sub-
ect, it is possible to ﬁnd observational studies of prospective
nd retrospective cohort that have been mostly published
efore the RCTs evaluated in this review and, in general,
howed lower rates of recurrent thrombotic events in patients
eceiving warfarin with INR> 3 compared to those receiving
nticoagulant therapy at a lower intensity (INR < 3).13–19,32
Study or subgroup
High intensity
Events
8 56 2 58 39.8%
55 60.2%
100.0%
3
5
54
110 11 3
6
14
Crowther et al., 2003
Finazzi et al., 2005
Total (95% CI)
Total events
Heterogeinity: Chi2 = 0.48, df = 1 (P=.49); I2 = 0%
Test for Global effect : Z = 2.10  (P=. 04)
Total Events Total Weight
Moderate intensity
Figure 2 – Graph of meta-analysis (Forest Plot) for comp
58115614 57.7% 
55 42.3%
100.0%
8
19
54
110 113
15
29
Crowther  et al.. 2003
Finazzi et al.. 2005
Total (95% CI)
Total events
Test for Global effect : Z = 1.71 (P=. 09)
Study or subgroup
High intensity
Events Total Events  Total  Weight 
Moderate intensity
Heterogeinity: Chi2 = 0.49, df = 1 ( P=.48); I2
Figure 3 – Graph of meta-analysis (Forest Plot) for comntensity; NA, not assessed.
In fact, the restrospective cohort study by Rosove et al.14
evaluated 70 patients with APS and concluded that warfarin
therapy of intermediate/high intensity may provide greater
antithrombotic protection compared to the use of warfarin
of low/intermediate intensity. However, this work, besides
having a retrospective nature, included patients without diag-
nostic criteria for APS as the population of study, weakening
such scientiﬁc evidence. In 1995, Khamashta et al.,13 retro-
spectively evaluating 147 patients with APS, also showed, in
their study, more  efﬁcacy in preventing recurrent thrombotic
events in patients receiving warfarin with INR> 3 compared to
those treated with anticoagulant therapy of lower intensity.
On the other hand, the prospective study by Ames et al.33
demonstrated that HI oral anticoagulation in patients with
APS was not better than the conventional treatment in the sec-
ondary prevention of thrombosis. This work followed, for eight
years, 67 patients with APS, 89 with hereditary thrombophilia,
and 24 with mitral valve replacement.
Another conclusion obtained from the analysis of observa-
tional studies was greater trend to recurrence of thrombotic
events of those patients who had arterial events. These indi-
viduals would therefore have higher cardiovascular risk and
would require a more  aggressive therapy. However, the retro-
spective study that reached this conclusion did not require
4.14 [0.92. 18.67]
2.04 [0.54. 7.73]
2.88 [1.07. 7.71]
0.01
Favourable to
high intensity
Favourable to moderate
intensity
10.1 10 100
Risk ratio
M-H, Fixed, 95% CI
Risk ratio
M-H, Fixed, 95% CI
arative analysis of thrombotic events occurrence.
1.32 [0.66. 2.65]
1.91 [0.88. 4.13]
1.57 [0.94. 2.63]
0.01 0.1 1 10 100
Risk ratio
M-H, Fixed, 95% CI
Risk ratio
M-H, Fixed, 95% CI 
Favourable to
high intensity
Favourable to moderate
intensity
parative analysis of total bleeding occurrence.
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3 56 4 58 56.9% 0.78 [0.18. 3.32]
0.68 [0.12. 3.90]
0.73 [0.24. 2.24]
55 43.1%
100.0%
0.01 0.1 1 10 100
3
7
54
110 113
2
5
Crowther  et al.. 2003
Finazzi et al.. 2005
Total (95% CI)
Total events
Test for Global effect: Z = 0.54 (P=.59)
Study or subgroup
High intensity
Events Total Events  Total  Weight 
Risk ratio
M-H, Fixed, 95% CI
Risk ratio
M-H, Fixed, 95% CI 
Moderate intensity
Favourable to
high intensity
Favourable to moderate
intensity
Heterogeinity: Chi2 = 0.01, df = 1 ( P=.91); I2 = 0%
Figure 4 – Graph of meta-analysis (Forest Plot) for comparative analysis of major bleeding occurrence.
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Finazzi et al.. 2005
Total (95% CI)
Total events
Test for Global effect : Z = 2.30 (P=.02)
Study or subgroup
High intensity
Events Total Events  Total Weight 
Risk ratio
M-H, Fixed, 95% CI
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M-H, Fixed, 95% CI 
Moderate intensity
Favourable to
high intensity
Favourable to moderate
intensity
Heterogeinity: Chi2 = 0.51, df = 1 ( P=.48); I2= 0%
Figure 5 – Graph of meta-analysis (Forest Plot) for comparative analysis of minor bleeding occurrence.
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Test for Global effect : Z = 0.41 (P=.68)
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Favourable to
high intensity
Favourable to moderate
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Heterogeinity: Chi2 = 0.5, df = 1 ( P=.82); I2= 0%
t) foFigure 6 – Graph of meta-analysis (Forest Plo
the fulﬁlling of diagnostic criteria for APS as a prerequisite for
selection of patients.17
Regarding the frequency of bleeding events, the study by
Ruiz-Irastorza et al.15 found similar results of major hem-
orrhage in rats treated with warfarin according to INR ≥ 3.5.
Moreover, the work by Ames et al.,33 Khamashta et al.,13 Derk-
sen et al.,16 Mun˜oz et al.18 and Girón-Gonzáles et al.32 showed
higher rates of bleeding in patients treated with HI antico-
agulant, with INR rates ranging from 3-7.5 at the moment of
bleeding.
However, we  must be aware of the importance of conduct-
ing systematic reviews nowadays, as they minimize potential
biases due to their rigid methodology, enabling the gathering
of the best scientiﬁc evidence that will be the foundation of
health care decision-making. The meta-analysis, in its turn,
allows better assessment of the evidence found in a liter-
ature review and of a possible heterogeneity of the results
presented.34,35 Therefore, this feature allows improving pre-
cision and accuracy in the estimate of treatment effect,
increasing its statistical power.35
One of the advantages of this review was the very restrictive
selection criteria, which allowed a more  accurate and reliable
analysis of results. Thus, there was the exclusion of studies
with designs different from that of randomized clinical tri-
als, such as case reports, case series, case-control studies,
retrospective, cross-sectional and cohort studies (the latterr comparative analysis of death occurrence.
was excluded for not allowing the evaluation of interven-
tions).
Another beneﬁt arising from the design of the selected
studies is the fact that these are multicenter studies, involving
a total of 39 clinical centers, including cities in Europe, Canada,
United States and Argentina, which brings external validity to
the data found. Furthermore, the study by Crowther et al.30
presented double-blind design, favoring further recognition of
the value of its results.
On the other hand, some important limitations of the eval-
uated studies should be highlighted. Namely, the study by
Finazzi et al.31 was not double-blind (they used ad hoc com-
mittee of clinical experts blinded to the treatment adopted),
which favors outcome biases. Moreover, the same work inter-
rupted clinical trial early, because of patients leaving the study
due to adverse effects, or patient or physician refusal to keep
the protocol.
Another aspect to be considered is that the study by
Crowther et al.30 failed to analyze the effectiveness of war-
farin in the ﬁrst three months after the ﬁrst thrombotic event
in patients involved in the study. This limitation was due to the
need, set during the study protocol, to perform two  tests for
APLs with an interval of three months. Additionally, patients
with high risk of bleeding, such as those with prior stroke,
thrombocytopenia (<50,000 mm3) and gastrointestinal bleed-
ing in the past three months, were excluded from this work
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n the same way that, in both studies, patients with recurring
vents, even during the use of anticoagulant prophylaxis, were
xcluded from clinical trials. Thus, many  patients with severe
ases of the disease were not included in the studies.
It is surprising to note that, in the study by Crowther et
l.,30 INR targets were not achieved in 43% of the time in
atients randomized to the HI warfarin group, what can per-
ectly explain the higher incidence of thrombosis in this group
hat was “undertreated”. In the study by Finazzi et al.,31 such
nformation was not found. Another possible explanation for
hese results would be poor randomization, for example, the
iased allocation of subjects, where the most severe ones
ould have been distributed to the HI group.
A further negative character of both studies is that they
ere developed intending to demonstrate the superiority of
nticoagulant treatment with warfarin in high doses. How-
ver, the results presented in the work by Crowther et al.30
how similarities between both intensities of anticoagulation.
dditionally, the study by Finazzi et al.31 found even worse
utcomes in the HI group.
The evidence found in the studies included in this
eview should be carefully evaluated in patients with arte-
ial thrombosis, since venous thromboembolic events were
he prevalent, representing about 70% of cases in both stud-
es. Therefore, a suggestion for future clinical studies in this
rea is the unique inclusion of patients with arterial events,
onsidering that the results of both previous studies already
arried out may be more  appropriately applied in patients with
enous events.
All the difﬁculties enumerated should be milded because
his is an uncommon disease. In fact, the APS has an esti-
ated prevalence of 40-50 cases per 100,000 people.36 Thus,
he two scientiﬁc papers included in this meta-analysis rep-
esent the best medical evidence available at the time. And
et, this evidence should be valued as prospective studies
ith large numbers of participants and presenting appropri-
te criteria for selection, inclusion and exclusion are unlikely
o occur.
In brief, the present meta-analysis compared two different
ntensities of anticoagulation in APS with thrombotic event
nd demonstrated that patients on HI warfarin (INR: 3-4) had
ore  thrombotic events (although about 40% of this group
ere “undertreated”) and minor bleeding. This ﬁnding pro-
ides evidence of usefulness for clinical practice, in the sense
hat, in individuals with APS and prevalence of venous events,
he use of MI  anticoagulation (INR: 2.0-3.0) is more  appropriate.
oreover, such evidence may not yet be extended to patients
ith arterial events, due to the limited representation of this
ample of subjects in the two clinical trials included in this
eta-analysis. We  therefore suggest the conduction of RCTs
nvolving patients with APS and prevalence of arterial throm-
osis.unding
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